This article is more than 5 years old. Information may no longer be current.
Cosentyx shows efficacy in patients with psoriasis after treatment pause
Click Here to Manage Email Alerts
Many patients with moderate-to-severe psoriasis retreated with Consentyx regained previous levels of efficacy after 16 weeks following a relapse during a treatment pause, according to a poster presentation at the American Academy of Dermatology Annual Meeting in Orlando, Florida.
Andrew Blauvelt, MD, MBA, president of the Oregon Medical Research Center, and colleagues presented data for patients retreated with the 300-mg dose of Consentyx (secukinumab, Novartis) following relapse for up to 2 years.
“This study addresses a common issue in clinical practice that happens when plaque psoriasis patients are on biologic therapy and have to stop for any number of reasons, and then re-start the biologic,” Blauvelt stated in a press release from Novartis. “Importantly, we found that stopping and re-starting Consentyx led to good re-capture of clinical responses. Low immunogenicity associated with Consentyx may offer a partial explanation of these results and warrants further analysis.”
Most patients with the highest response levels to secukinumab (Psoriasis Area Severity Index score of 90 [PASI 90] or PASI 100) after 1 year of treatment on the 300-mg dose regained a response of PASI 75 or higher at 12 to 16 weeks after treatment re-initiation.
For patients who had previously achieved PASI 75 and relapsed after treatment discontinuation, 94% had regained PASI 75 response at week 16 of retreatment, while 79% of prior PASI 900 responders regained PASI 90 response and 67% of PASI 100 responders regained PASI 100 response during the period, according to the release from Novartis.
The safety profile was consistent with previous reports, and no anti-drug antibodies were observed during retreatment, the researchers reported.
“Secukinumab retreatment rapidly restored efficacy in subjects relapsing after being withdrawn form therapy,” Blauvelt and colleagues wrote in their conclusion. “The majority of subjects who exhibit the highest levels of response to secukinumab (PASI 90, PASI 100) can expect to regain a high response level (PASI 75 or higher) 12-16 weeks after treatment interruption and resumption of therapy.”
References:
www.novartis.com
Blauvelt A, et al. Secukinumab Retreatment Shows Rapid Recapture of Treatment Response: An Analysis of a Phase 3 Extension Trial in Psoriasis. Presented at: American Academy of Dermatology Annual Meeting; March 3-7; Orlando.
Disclosure: Blauvelt reports financial ties with AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli-Lilly, Jannsen Ortho Biotech, Merck, Novartis, Pfizer and Sandoz.